This clinical trial is testing different doses of a chemotherapy drug called melphalan for patients with a type of cancer called multiple myeloma. Multiple myeloma affects the plasma cells in bone marrow. Patients in this study will receive a stem cell transplant, which means replacing damaged blood-forming cells with healthy ones. The study uses a special method called pharmacokinetic analysis to find the best dose for each patient by checking how their body processes melphalan. This could help make the treatment more personalized and effective.
Key Points:
- Participants will have multiple visits over a 90-day period after treatment starts.
- This study involves chemotherapy and a stem cell transplant, which may have side effects.
- Participants can help researchers learn how to improve treatment for others in the future.
How understandable was the trial content above?
Hard to understand
Easy to understand